skip to Global Navigation Bar
skip to main content
HOME
CONTACT US
SITEMAP
KOREAN
Global Business
Introduction
Strategy
Manufacturing
Contact Us
R&D
Introduction
Global R&D Centers
R&D Organization
Pipeline
CDMO
Introduction
Manufacturing Sites
Business Model
Service Range
Products
Global Brand
Products Search
In-License
Introduction
Strategy
No.1 Position
Core-Competency
Licensed Products
Partnership
Investors
Management information
Financial information
Stock condition
IR information
About Us
Company Profile
CEO Message
Recruitment
Press Release
Company Profile
CEO Message
Recruitment
Press Release
News
PR Video
Home > About Us > Recruitment >
News
뉴스
No
Subject
Data
283
A global symposium pays attention to Nav 1.7 Chronic Pain Treatment, DWP17061.
2019-06-25
282
Daewoong Pharmaceutical’s ‘Nabota’ secured application to blepharospasm.
2019-06-24
281
Daewoong Pharmaceutical initiates development of new medication for hearing impairment (First in Class) with Yonsei University based on the ion channel platform technology.
2019-06-13
280
Daewoong Pharmaceutical’s diabetes treatment, ‘DWP16001,’ approved for clinical test phase 2 in Korea.
2019-05-31
279
Daewoong Pharmaceutical’s ‘Urusa 300mg’ secured application to ‘prevention of gallbladder stones after gastrectomy’ for the first time in the world.
2019-05-29
278
Daewoong Pharmaceutical’s Botulinum Toxin officially released in the U.S... targeting the world’s largest Botulinum Toxin market.
2019-05-16
277
Daewoong Pharmaceutical has released ‘Olomax’ for both hypertension and hyperlipidemia
2019-05-03
276
Daewoong Pharmaceutical hosted a symposium titled ‘NABOTA Sparkling Night’ in Thailand
2019-05-03
275
Daewoong Pharmaceutical’s botulinum toxin about to be released in Europe with European CHMP’s recommendation for approval
2019-04-26
274
Daewoong Pharmaceutical announced the excellence of Nabota through an overseas specialist training program.
2019-04-15
1
/
2
/
3
/
4
/
5
/
6
/
7
/
8
/
9
/
10
/
News Search
subject
content